Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Nanomedicine (2)
- Analgesics Opioid (1)
- Anti-a4b7 monoclonal antibody (1)
- Antibodies Monoclonal (1)
- Dolutegravir (1)
-
- Emtricitabine-triphosphate (1)
- Esterification (1)
- Gut-Brain Axis (1)
- HIV (1)
- HIV-1 (1)
- Human Immunodeficiency Virus (HIV) (1)
- LASER ART (1)
- Long-Acting (1)
- Macrophage (1)
- Microbiome (1)
- Microbiota (1)
- Opioids (1)
- Palmitoyl chloride (1)
- Prodrug (1)
- Simian Immunodeficiency Virus (SIV) (1)
- Viral reservoirs (1)
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Gut Commensals Modulate Siv/Shiv Pathogenesis And Therapeutics, Samuel Johnson
Gut Commensals Modulate Siv/Shiv Pathogenesis And Therapeutics, Samuel Johnson
Theses & Dissertations
Despite significant advancements in combination antiretroviral therapy (cART), ongoing inflammation in the brain and gut remain two of the most significant hurdles in the health of people living with human immunodeficiency virus (HIV). Additionally, a viral reservoir in each compartment inhibits cure efforts by allowing rapid viral rebound following cART interruption. Emerging understanding of the gut-brain axis (GBA) implicates each compartment in the modulation of the other in a complex bi-directional interaction mediated by vagus innervation, circulating lymphocytes, and microbiome composition and biproducts. Using multiple models of the simian (and simian-human) immunodeficiency virus (SIV/SHIV) and therapeutic intervention, I present how …
Synthesis And Characterization Of A Long-Acting Emtricitabine Prodrug Nanoformulation, Ibrahim M. Ibrahim
Synthesis And Characterization Of A Long-Acting Emtricitabine Prodrug Nanoformulation, Ibrahim M. Ibrahim
Theses & Dissertations
The introduction of highly active antiretroviral therapy led to a paradigm shift in the management of HIV/AIDS changing a disease considered “a death sentence” to “a manageable chronic disease”. Nevertheless, challenges exist for successful treatment of HIV, including patient adherence to the complex daily regimens and the inability of current formulations to target viral sanctuaries. Introduction of nanoformulated antiretroviral therapy (ART) is a promising alternative to tackle these challenges. Our laboratory has been focusing on developing long-acting (LA) nanoformulated antiretrovirals and has succeeded in developing LA integrase inhibitors. However, challenges for this approach extend to a range of short-acting hydrophilic …
Development Of A Long-Acting Nanoformulation Of Dolutegravir For Prevention And Treatment Of Hiv-1 Infection, Brady Sillman
Development Of A Long-Acting Nanoformulation Of Dolutegravir For Prevention And Treatment Of Hiv-1 Infection, Brady Sillman
Theses & Dissertations
Dolutegravir (DTG) is a potent human immunodeficiency virus type 1 (HIV-1) integrase strand-transfer inhibitor (INSTI) with a high barrier to viral drug resistance. However, opportunities to improve its profile abound. These include extending the drug’s apparent half-life, increasing penetrance to “putative” viral reservoirs, and reducing inherent toxicities. These highlight, in part, the need for long-acting, slow effective release antiretroviral therapy (LASER ART) delivery schemes. A long-acting (LA) DTG was made by synthesizing a hydrophobic and lipophilic prodrug encased with poloxamer (P407) surfactant. This modified DTG (MDTG) reduced systemic metabolism and polarity, increased lipophilicity and membrane permeability, improved encapsulation, and formed …